Pharmaceuticals News and Research

RSS
FDA approves Sagent's bacitracin for pneumonia and empyema

FDA approves Sagent's bacitracin for pneumonia and empyema

Avexa halts HIV drug trials

Avexa halts HIV drug trials

China Biologic subsidiary Shandong Taibang receives approval to build two new plasma stations

China Biologic subsidiary Shandong Taibang receives approval to build two new plasma stations

NovaBay first-quarter net loss increases to $1.6 million

NovaBay first-quarter net loss increases to $1.6 million

NIH awards PLx Pharma multiple grants for development of GI safer NSAIDs

NIH awards PLx Pharma multiple grants for development of GI safer NSAIDs

Pro-Pharmaceuticals reports net loss applicable to common stock of $2.8M for first-quarter 2010

Pro-Pharmaceuticals reports net loss applicable to common stock of $2.8M for first-quarter 2010

Bioniche third-quarter consolidated revenues increase 111% to $15.6 million

Bioniche third-quarter consolidated revenues increase 111% to $15.6 million

Patient enrollment completed in Phase 2 clinical trial of orBec for prevention of acute GVHD

Patient enrollment completed in Phase 2 clinical trial of orBec for prevention of acute GVHD

Merck hosts R&D and Business Briefing

Merck hosts R&D and Business Briefing

Key mechanisms for delivery of LNP-encapsulated siRNAs to the liver

Key mechanisms for delivery of LNP-encapsulated siRNAs to the liver

MicroStockProfit.com releases investment report featuring Hemispherx Biopharma

MicroStockProfit.com releases investment report featuring Hemispherx Biopharma

New approach to harness and modulate enzyme activity

New approach to harness and modulate enzyme activity

Drug-releasing stents do not result in fewer deaths or subsequent heart attacks after angioplasty

Drug-releasing stents do not result in fewer deaths or subsequent heart attacks after angioplasty

Evotec first-quarter operating loss decreases 93% to € 1.5 m

Evotec first-quarter operating loss decreases 93% to € 1.5 m

Meda acquires European rights to new imiquimod formulation for AK from Graceway Pharmaceuticals

Meda acquires European rights to new imiquimod formulation for AK from Graceway Pharmaceuticals

Response Genetics, GSK sign non-exclusive license agreement for BRAF mutational analysis technology

Response Genetics, GSK sign non-exclusive license agreement for BRAF mutational analysis technology

Optivia Biotechnology launches OptiDDI Suite for assessing transporter-related DDIs

Optivia Biotechnology launches OptiDDI Suite for assessing transporter-related DDIs

New computer-based tool developed to benefit cancer patients

New computer-based tool developed to benefit cancer patients

PharmedOut to host conference to explore influence of pharmaceutical industry on medical education

PharmedOut to host conference to explore influence of pharmaceutical industry on medical education

MIT featured in U.S. Equity News

MIT featured in U.S. Equity News

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.